CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 157 enrolled
Drug / intervention
Pembrolizumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02721732
NCT02721732Phase 2Active
CompareCT.gov

Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors

M.D. Anderson Cancer Center·interventional·Posted Mar 29, 2016·Updated Jan 29, 2026

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Pembrolizumab, and 1 other intervention for Advanced Malignant Solid Neoplasm and 18 related conditions. Active but no longer recruiting, targeting 157 participants across 1 site.

Detailed Summary

This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may block specific proteins found on white blood cells which may strengthen the immune system and control tumor growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Solid Neoplasm, Metastatic Paraganglioma, Metastatic Penile Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Small Cell Carcinoma, Stage III Adrenal Cortex Carcinoma AJCC v7, Stage IV Adrenal Cortex Carcinoma AJCC v7, Stage IV Penile Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Solid Neoplasm, Vascular Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2Active
20162017201820192020202120222023202420252026202720282029
First PostedMar 29, 2016
Enrollment StartAug 15, 2016
Primary CompletionDec 31, 2028
TodayJul 2, 2026
Enrollment to primary: 12.4 yearsPosted 10.3 years agoPrimary completion in 2.5 years

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Pembrolizumabbiological

Given IV

Questionnaire Administrationother

Ancillary studies